122 related articles for article (PubMed ID: 6864917)
1. Acetylator phenotype in human bladder cancer.
Miller ME; Cosgriff JM
J Urol; 1983 Jul; 130(1):65-6. PubMed ID: 6864917
[TBL] [Abstract][Full Text] [Related]
2. Hepatic acetylator phenotype in bladder cancer patients.
Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
[TBL] [Abstract][Full Text] [Related]
3. The association of the slow acetylator phenotype with bladder cancer.
Evans DA; Eze LC; Whibley EJ
J Med Genet; 1983 Oct; 20(5):330-3. PubMed ID: 6644762
[TBL] [Abstract][Full Text] [Related]
4. Overrepresentation of the slow acetylator phenotype in painters suffering from urinary bladder cancer.
Golka K; Kempkes M; Flieger A; Blaszkewicz M; Bolt HM
Med Lav; 1997; 88(5):425-6. PubMed ID: 9489306
[No Abstract] [Full Text] [Related]
5. [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients].
Schöps W; Prior V; Golka K; Blaszkewicz M; Cascorbi I; Roots I; Bolt HM; Kierfeld G
Urologe A; 1997 Jan; 36(1):64-7. PubMed ID: 9123684
[TBL] [Abstract][Full Text] [Related]
6. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
[TBL] [Abstract][Full Text] [Related]
8. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl.
Flammang TJ; Couch LH; Levy GN; Weber WW; Wise CK
Carcinogenesis; 1992 Oct; 13(10):1887-91. PubMed ID: 1423849
[TBL] [Abstract][Full Text] [Related]
9. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
10. [The acetylator phenotype in patients with urinary bladder cancer].
Wich H; Franke G; Grimm U; Siegmund W
Z Urol Nephrol; 1989 Nov; 82(11):597-9. PubMed ID: 2618184
[TBL] [Abstract][Full Text] [Related]
11. Survey of the human acetylator polymorphism in spontaneous disorders.
Evans DA
J Med Genet; 1984 Aug; 21(4):243-53. PubMed ID: 6387123
[TBL] [Abstract][Full Text] [Related]
12. Acetylation phenotypes and bladder cancer.
Hanke J; Krajewska B
J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
[TBL] [Abstract][Full Text] [Related]
13. Acetylation phenotypes in patients with bladder carcinoma.
Bicho MP; Breitenfeld L; Carvalho AA; Manso CF
Ann Genet; 1988; 31(3):167-71. PubMed ID: 3265609
[TBL] [Abstract][Full Text] [Related]
14. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
Wolf H; Lower GM; Bryan GT
Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
[TBL] [Abstract][Full Text] [Related]
15. Acetylator phenotype in bladder cancer.
Miller ME
Lancet; 1982 Dec; 2(8311):1348. PubMed ID: 6128635
[No Abstract] [Full Text] [Related]
16. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
Sone M
Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
[TBL] [Abstract][Full Text] [Related]
17. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors.
Mommsen S; Aagaard J
Cancer Lett; 1986 Aug; 32(2):199-205. PubMed ID: 3756846
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England.
Probert JL; Persad RA; Greenwood RP; Gillatt DA; Smith PJ
Br J Urol; 1998 Nov; 82(5):660-6. PubMed ID: 9839580
[TBL] [Abstract][Full Text] [Related]
20. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.
Pink JC; Messing EM; Reznikoff CA; Bryan GT; Swaminathan S
Drug Metab Dispos; 1992; 20(4):559-65. PubMed ID: 1356735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
